Volume : 11, Issue : 01, January – 2024
Title:
A REVIEW OF NANOCARRIER-BASED CNS DELIVERY SYSTEMS
Authors :
Mohammad Ashhar, Ajip A. Rathod, Vinayak A. Katekar, Dr. Swati P. Deshmukh
Abstract :
Nanocarriers are nano-sized structures designed to transport and deliver various payloads, such as drugs or imaging agents, to specific targets within the body. They offer advantages like enhanced drug stability, controlled release, and targeted delivery, minimizing side effects. This abstract encapsulates the versatile applications and promising potential of nanocarriers in advancing drug delivery systems and medical treatments. These nanocarriers, often composed of lipids, polymers, or inorganic materials, enable precise control over drug release kinetics, improving therapeutic efficacy.
These nanocarriers, often composed of lipids, polymers, or inorganic materials, enable precise control over drug release kinetics, improving therapeutic efficacy. Their size and surface properties can be tailored for optimal interactions with biological systems, facilitating targeted delivery to specific tissues or cells. Furthermore, ongoing research explores multifunctional nanocarriers, integrating diagnostic capabilities or stimuli-responsive features, contributing to the evolution of personalized and efficient medical interventions.
Keywords: nanocarriers, specific targets,polymers,lipids, inorganic domaterials, optimal interaction.
Cite This Article:
Please cite this article in press Mohammad Ashhar et al., A Review Of Nanocarrier-Based CNS Delivery Systems, Indo Am. J. P. Sci, 2024; 11 (01).
Number of Downloads : 10
References:
[1]“Nanoparticles for drug delivery to the central nervous system.” Silva GA. Nanomedicine, 2007.
[2]“Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease. Re F, Gregori M, Masserini M. Nanosciences and Nanotechnology, 2009.
[3]“Nanoformulations for drug delivery in Parkinson’s disease.” Chopra K, Misra S, Kuhad A.Neuroimmune Pharmacology, 2013.
[4]“Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.” Sánchez-López E, Espina M, Doktorovová S, Souto EB, García ML. Pharmaceutics, 2020.
[5] Kermani, F. CNS Drugs and CNS Markets: A Strategic Guide to CNS Disorders, Markets and Therapies, 1999.http://www. Europe-Anpharmaceutical.com
[6] Pardridge, W. M. Brain Drug Targeting: The Future of Brain DrugDevelopment, Cambridge University Press: Cambridge, UK 2001.
[7] World Health Organization, The Global Burden of Disease Project
[8] Sherwood, L. Human Physiology: From Cells to Systems, Wad-Sworth Publishing Company: Belmont, UK 1997.
[9] Pardridge, W. M. Peptide Drug Delivery to the Brain, Raven Press:New York, NY 1991.
[10] Begley, D. J. Acta Paediatr. Suppl., 2003, 92, 83-91.
[11] Sherwood, L. Fundamentals of Physiology: A Human Perspective,West Publishing Company: St. Paul, MN 1995.
[12] Burke, M.; Langer, R.; Brim, H. Central Nervous System: Drug Delivery to Treat, John Wiley & Sons, Inc.: New York, NY 1999.
[13] Tusji, A. The Blood-Brain Barrier and Drug Delivery to the CNS,Marcel Dekker, Inc.: New York, NY 2000.
[14] Abbott, N. J.; Romero, I. A. Mol. Med. Today, 1996, 2, 106-113.
[15] Schinkel, A. H. Adv. Drug Deliv. Rev., 1999, 36, 179-194.
[16] Pardridge, W. M. Pharmacol. Toxicol., 1992, 71, 3-10.
[17] Speiser, P. P. Methods Find. Exp. Clin. Pharmacol., 1991, 13, 337-342.
[18] Woo, S. Y.; Dilliplane, P.; Rahman, A.; Sinks, L. F. Cancer DrugDeliv., 1983, 1, 59-62.
[19] Allen, T. M.; McAllister, L.; Mausolf, S.; Gyorffy, E. Biochem.Biophys. Acta, 1981, 643, 346-362.
[20] Casacchia, M.; Meco, G.; Pirro, R.; Di Cesare, E.; Allegro, A.;Cusimano, G.; Marola, W. Int. Pharmacopsychiat., 1982, 17, 274-279.
[21] Beaumier, P. L.; Hwang, K. J. Biochim. Biophys Acta, 1983, 731,23-30.
[22] Harsanyi, B. B.; Hilchie, J. C.; Mezei, M. J. Dent. Res., 1986, 65,1133-1141.
[23] Murray, K. D.; McQuillin, A.; Stewart, L.; Etheridge, C. J.; Coo-Per, R. G.; Miller, A. D.; Gurling, H. M. Gene Ther., 1999, 6, 190-197.
[24] Cao, Y. J.; Shibata, T.; Rainov, N. G. Gene Ther., 2002, 9, 415-419.